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Summary
Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy
for which allogeneic haematopoietic stem cell transplantation (allo-HSCT)
represents the only curative option. We describe transplant outcomes in 42
patients reported to the European Society for Blood and Marrow Trans-
plantation (EBMT) registry who underwent allo-HSCT for aCML between
1997 and 2006. Median age was 46 years. Median time from diagnosis to
transplant was 7 months. Disease status was first chronic phase in 69%.
Donors were human leucocyte antigen (HLA)-identical siblings in 64% and
matched unrelated (MUD) in 36%. A reduced intensity conditioning was
employed in 24% of patients. T-cell depletion was applied in 87% and 26%
of transplants from MUD and HLA-identical siblings, respectively. Accord-
ing to the EBMT risk-score, 45% of patients were ‘low-risk’, 31% ‘interme-
diate-risk’ and 24% ‘high-risk’. Following allo-HSCT, 87% of patients
achieved complete remission. At 5 years, relapse-free survival was 36% and
non-relapse mortality (NRM) was 24%, while relapse occurred in 40%.
Patient age and the EBMT score had an impact on overall survival.
Relapse-free survival was higher in MUD than in HLA-identical sibling
HSCT, with no difference in NRM. In conclusion, this study confirmed
that allo-HSCT represents a valid strategy to achieve cure in a reasonable
proportion of patients with aCML, with young patients with low EBMT
risk score being the best candidates.
Keywords: allogeneic transplantation, atypical chronic myeloid leukaemia,
Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN), Ph-negative CML:
BCR-ABL1-negative.
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Philadelphia-negative BCR-ABL1 negative chronic myeloid
leukaemia (CML), usually called atypical CML (aCML), rep-
resents a very rare disease entity with aggressive clinical char-
acteristics that usually confer a dismal prognosis (Kurzrock
et al, 1990; Onida et al, 2002; Muramatsu et al, 2012; Wang
et al, 2014). Even though high-throughput molecular studies
have recently generated new insights into possible patho-
genetic mechanisms (Maxson et al, 2013; Piazza et al, 2013;
Li et al, 2014; Gambacorti-Passerini et al, 2015), which in
the near future may translate into innovative targeted thera-
pies (Gotlib et al, 2013), at present allogeneic haematopoietic
stem cell transplantation (allo-HSCT) remains the only cura-
tive treatment option (Mittal et al, 2004). The disease is
extremely rare, especially in patients younger than 65 years,
and outcome after allo-HSCT has been reported only in
small single-institution series (Koldehoff et al, 2004; Mittal
et al, 2004; Lim et al, 2013). In this retrospective analysis, we
describe allo-HSCT outcomes in patients with Philadelphia-
negative, BCR-ABL1-negative CML reported to the European
Society for Blood and Marrow Transplantation (EBMT)
registry.
Patients and methods
This study, conducted on behalf of the Chronic Malignancies
Working Party of the EBMT, was based on data from 42
patients with CML who underwent allogeneic stem cell trans-
plantation from 1997 to 2006 and were reported as negative
for the presence of the t(9;22)(q34;q11) cytogenetic translo-
cation (Philadelphia chromosome) and for the BCR-ABL1
transcript.
Main clinical and transplant characteristics were analysed
for their association with different outcomes, i.e. overall sur-
vival (OS), relapse-free survival (RFS), relapse incidence
(REL) and non-relapse mortality (NRM). All outcomes were
calculated from the day of allo-HSCT. The Kaplan–Meier
method was used for estimates of OS and RFS. REL and
NRM were analysed by cumulative incidence estimates,
considering these outcomes as each other’s competing event.
The log-rank test was used to compare survival curves and
Cox-model based score tests were used to compare REL and
NRM between groups (both tests being equivalent in models
comparing a single factor).
The characteristics of interest are listed in Table I. Specifi-
cally, we included the covariates age (≤45 / >45 years), num-
ber of treatment lines preceding allo-HSCT (≤1 vs. >1), time
interval elapsed between diagnosis and transplantation (<6 /
6–12 / >12 months), disease status at transplant (first
chronic phase/more advanced phases), donor type [matched
unrelated donor (MUD) versus human leucocyte antigen
(HLA)-identical sibling], conditioning intensity [reduced
intensity conditioning (RIC) versus standard myeloablative
conditioning (MAC)], stem cell source [peripheral blood ver-
sus bone marrow (BM)], T-cell depletion (no/yes) and HSCT
EBMT risk-score (0–2 / 3 / 4–7).
Calculations were performed with SPSS v.20 software
(IBM Corp. Armonk, NY, USA). Cumulative incidences were
calculated by means of SPSS macros developed by the
Department of Medical Statistics and Bioinformatics of the
Leiden University Medical Centre (Leiden, the Netherlands),
on the basis of the hazard estimates from the Cox models. R
version 3.3.0, with package ‘prodlim’ (R Foundation for Sta-
tistical Computing, Vienna, Austria), was used to create the
figures. Institutional review board approval was obtained
locally from all participating institutions.
Results
Table I lists the main patient, disease and transplant charac-
teristics of the 42 patients included in the study. At the time
of transplantation, 55% (n = 23) and 38% (n = 16) of
patients were older than 45 and 50 years, respectively. At
diagnosis, cytogenetics were missing in four patients (all
reported as BCR/ABL1 negative).
A RIC regimen was employed in 24% of patients
(n = 10), with a median age of 58 years (range 34–68),
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whereas MAC was preferred in all the others (median age
46 years, range 27–59). In the latter group, total body irradi-
ation was included in the conditioning regimen in 56% of
patients (n = 18). The stem cell source was the BM in 33%
(n = 14) of patients, and was more often selected within the
MAC than in the RIC transplant setting (41% vs. 10%,
respectively). A T-cell depletion strategy was applied in 52%
of cases (n = 22), and was more frequent in patients trans-
planted from a MUD than from an HLA-identical sibling
(87% vs. 26%, respectively).
When the EBMT risk-score (Gratwohl et al, 1998) at
transplant was calculated, 45% of patients were classified as
‘low-risk’ (score = 0–2), 31% were ‘intermediate-risk’
(score = 3) and 24% were ‘high-risk’ (4–7).
Primary graft failure was reported in two patients (5%), of
whom one was transplanted from an HLA-identical sibling
and one from a MUD. Following allo-HCST, 26 of the 30
evaluable patients achieved a complete remission of their dis-
ease, whereas a partial remission was reported in two
patients. Two patients were classified as non-responders.
Acute graft-versus-host disease (aGvHD) of grade II-IV
occurred in 12 patients, whereas overall chronic GVHD
Table I. Patient, disease and transplant characteristics.
Patients (n) 42
Sex (male/female) 23 (55)/19 (45)
Age (years) Median 46,
range 25–67
≤45 years 19 (45)
>45 years 23 (55)
Abnormal cytogenetics 9 (23)
Time from diagnosis to transplant (months) Median 7,
range 3–66
<6 months 11 (26)
6–12 months 18 (43)
>12 months 13 (31)
Splenectomy (pre-transplantation) 6 (19)
Pre- transplantation chemotherapy* 34 (94)
Disease stage at transplantation
CP1 29 (69)
CP2 4 (10)
AP 5 (12)
BP 4 (10)
Donor type (HLA-identical sibling/MUD) 27 (64)/15 (36)
Conditioning (MAC/RIC) 32 (76)/10 (24)
SC Source (BM/PB) 14 (33)/28 (67)
T-cell depletion (yes/no) 22 (52)/20 (48)
EBMT Score
Low (0–2) 19 (45)
Intermediate (3) 13 (31)
High (4–7) 10 (24)
Values in parenthesis are expressed in percentages.
AP, accelerated phase; BM, bone marrow; BP, blastic phase; CP1, first
chronic phase; CP2, second chronic phase; EBMT, European Society
for Blood and Marrow Transplantation; HLA, human leucocyte anti-
gen; MAC, myeloablative conditioning; MUD, matched unrelated
donor; PB, peripheral blood; RIC, reduced intensity conditioning.
*Out of 36 available.
Table II. Transplant, disease and survival outcome.
Transplant outcome*
Graft failure 2
Acute GvHD grade II–IV 12
Limited chronic GvHD 12
Extensive chronic GvHD 9
Disease outcome†
Complete response 26 (87%)
Partial response 2 (65%)
Non responder 2 (65%)
5-year outcome probability (95% confidence interval)
Overall survival 51% (35–66%)
Relapse-free survival 36% (21–51%)
Relapse incidence 40% (25–55%)
Non-relapse mortality 24% (11–37%)
GvHD, graft-versus-host disease.
*Number of patients in which this outcome was reported.
†Out of 30 evaluable patients.
Fig 1. (A) Five-year overall survival following allogeneic transplanta-
tion in 42 patients. (B) Five-year relapse-free survival following allo-
geneic transplantation in 42 patients.
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(cGVHD) was reported in 21 of the patients alive at
+100 days after transplantation (n = 37), being extensive in
nine of them (Table II).
Median OS following allo-HSCT was 70 months [95%
confidence interval (CI) 17–125] (Fig 1A). Median follow-up
of patients alive was 89 months. The percentage of patients
alive and relapse-free at 5 years after transplantation was
36% (Fig 1B) whereas NRM was 24%, and 40% experienced
a disease-relapse following transplantation. Of the latter sub-
group, 11 (26%) died from disease progression. Causes of
non-relapse mortality included GvHD (n = 1), infectious
complications (n = 5), organ damage/failure (n = 2) and
other reasons (n = 3).
With regard to the association of the analysed risk factors
with different outcomes (Tables III and IV), univariate analy-
sis identified an age effect on OS, with patients older than
45 years having a significantly lower probability of survival at
5 years (39%, 95% CI 19–59%), compared to the younger
subgroup (66%, 95% CI 44–88%; P = 0036) (Fig 2). OS was
also significantly affected by the EBMT risk score: patients in
the high-risk group had a 5-year survival probability of 30%
(95% CI 2–58%), compared to 46% (95% CI 19–73%) for
patients in the intermediate risk group and 67% (95% CI 43–
88%) for low-risk patients (P = 0011) (Fig 3).
Donor type emerged as the only factor significantly asso-
ciated with REL and RFS, favouring patients transplanted
from an unrelated donor in comparison to those trans-
planted from an HLA-identical sibling. Relapses were signif-
icantly less frequent in patients transplanted with a MUD,
with 13% (95% CI 0–31%) experiencing relapse over
5 years, compared to 55% (95% CI 35–75%; P = 0012) in
the HLA-identical transplant group (Fig 4A). As a conse-
quence, patients transplanted with a MUD had a higher 5-
year RFS probability (60%, 95% CI 35–85%), compared to
patients transplanted from a HLA-identical donor (22%,
95% CI 5–39%; P = 0042) (Fig 4B). No difference in NRM
was observed between the HLA and MUD subgroups
(P = 089).
Table III. The impact of risk factors on OS and RFS at 5 years after allogeneic haematopoietic stem cell transplantation. Probabilities with 95%
confidence intervals are provided. Hazard ratios with corresponding 95% confidence intervals are given. For each risk factor, the reference cate-
gory is the first group. All P-values are from score tests based on Cox models testing overall differences. Significant risk factors are highlighted in
bold.
Risk factor
5-year OS 5-year RFS
Probability (95% CI) HR (95% CI) P Probability (95% CI) HR (95% CI) P
Overall 051 (035–066) 036 (021–051)
Age 0036 0093
≤45 years 066 (044–088) 051 (027–074)
>45 years 039 (019–059) 254 (103–627) 025 (007–043) 193 (089–419)
Donor type 0617 0042
HLA 046 (026–065) 022 (005–039)
MUD 060 (035–085) 08 (032–196) 060 (035–085) 041 (017–099)
EBMT score 0034 0327
1–2 065 (043–088) 043 (019–067)
3 046 (019–073) 19 (067–544) 031 (006–056) 145 (06–35)
4–5–6 030 (002–058) 362 (13–1007) 030 (002–058) 197 (079–492)
Time from Dx to Tx 0279 0910
<6 months 055 (025–084) 036 (008–065)
6–12 months 060 (037–083) 085 (029–254) 036 (012–059) 094 (038–235)
>12 months 037 (010–064) 179 (064–506) 037 (010–064) 114 (044–297)
Disease stage at Tx 0086 0071
CP1 057 (038–075) 043 (024–062)
Other phase 038 (012–065) 208 (088–492) 032 (016–049) 199 (093–428)
Stem cell source 0783 0723
BM 050 (024–076) 029 (005–052)
PB 051 (032–070) 114 (046–279) 040 (021–059) 087 (04–189)
Conditioning 0248 0584
MAC 045 (027–063) 032 (016–049)
RIC 070 (042–098) 049 (015–167) 050 (019–081) 076 (029–202)
T-cell depletion 0249 0884
No 060 (038–081) 034 (013–055)
Yes 043 (021–064) 165 (07–388) 039 (018–060) 095 (045–199)
95% CI, 95% confidence interval; BM, bone marrow; CP1, first chronic phase; DX, diagnosis; EBMT, European Society for Blood and Marrow
Transplantation; HLA, human leucocyte antigen; HR, hazard ratio; MAC, myeloablative conditioning; MUD, matched unrelated donor; OS, over-
all survival; PB, peripheral blood; RFS, relapse-free survival; RIC, reduced intensity conditioning; Tx, transplantation.
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Table IV. The impact of risk factors on REL and NRM at 5 years after allogeneic haematopoietic stem cell transplantation. Probabilities and
95% confidence intervals have been calculated as cumulative incidence functions in a competing risks setting. Cause specific hazard ratios with
corresponding 95% confidence intervals are given. For each risk factor, the reference category is the first group. All P-values stem from score tests
based on Cox models testing overall differences. Significant risk factors are highlighted in bold.
Risk factor
5 year REL 5 year NRM
Probability (95% CI) HR (95% CI) P Probability (95% CI) HR (95% CI) P
Overall 040 (024–055) 024 (011–037)
Age 0361 0122
≤45 years 039 (016–062) 011 (000–024)
>45 years 040 (020–061) 157 (059–414) 035 (015–054) 274 (072–1038)
Donor type 0012 0889
HLA 055 (035–075) 023 (007–039)
MUD 013 (000–031) 022 (006–079) 027 (004–049) 092 (026–318)
EBMT score 0875 0215
1–2 046 (022–070) 011 (000–025)
3 038 (012–065) 112 (037–342) 031 (006–056) 232 (052–1037)
4–5–6 030 (002–058) 137 (041–457) 040 (010–070) 356 (079–1602)
Time from Dx to Tx 0991 0864
<6 months 045 (016–075) 018 (000–041)
6–12 months 042 (018–066) 095 (03–299) 022 (003–041) 093 (021–417)
>12 months 032 (006–059) 102 (03–355) 031 (006–056) 134 (03–598)
Disease stage at Tx 0105 0384
CP1 036 (018–054) 021 (006–036)
Other phase 046 (019–073) 219 (083–577) 025 (010–040) 172 (05–594)
Stem cell source 0460 0143
BM 029 (005–052) 043 (017–069)
PB 046 (026–065) 152 (05–467) 014 (001–027) 042 (013–139)
Conditioning 0615 0805
MAC 042 (025–060) 025 (010–040)
RIC 030 (002–058) 073 (021–254) 020 (000–045) 083 (018–382)
T-cell depletion 0991 0804
No 041 (019–063) 025 (006–044)
Yes 038 (017–060) 101 (039–261) 023 (005–040) 086 (026–283)
95% CI, 95% confidence interval; BM, bone marrow; CP1, first chronic phase; DX, diagnosis; EBMT, European Society for Blood and Marrow
Transplantation; HLA, human leucocyte antigen; HR, hazard ratio; MAC, myeloablative conditioning; MUD, matched unrelated donor; NRM,
non-relapse mortality; PB, peripheral blood; REL relapse incidence; RIC, reduced intensity conditioning; Tx, transplantation.
Fig 2. Five-year overall survival following allogeneic transplantation
in 42 patients according to age (≤45 vs. >45 years).
Fig 3. Five-year overall survival following allogeneic transplantation
in 42 patients according to the European Society for Blood and Mar-
row Transplantation (EBMT) risk score.
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Discussion
Even if based on a limited population, this study includes
the largest series of patients undergoing allo-HSCT for aCML
assembled so far, both from related and unrelated donors.
Study limitations come from its retrospective nature, encom-
passing cases transplanted with a heterogeneity of condition-
ing regimens (both standard and reduced intensity) in
different stages of the disease (early or advanced), as well as
having received a variety of pre-transplant treatment courses,
possibly involving hydroxycarbamide, busulfan and a-inter-
feron; splenectomy was also performed in a minority of
patients. Nonetheless, considering that median OS of patients
with aCML in the largest series ever reported is only
24 months (Onida et al, 2002), results arising from this anal-
ysis with a substantial number of patients being alive (51%,
95% CI 35–66%), and around one-third alive and disease-
free 5 years after transplantation (36%, 95% CI 21–51%),
appear to be of particular interest.
With regard to the prognostic factors capable of predicting
post-transplant outcome, although their conclusive evalua-
tion would necessarily require a prospective study in a larger
patient population, our findings raise some interesting ques-
tions. Indeed, while longer survival was by no means unex-
pected in younger patients in comparison to their older
counterparts, the significantly reduced risk of relapse associ-
ated with the use of unrelated versus HLA-identical sibling
donor, also translating in a significantly longer RFS, is some-
how surprising. Hence, in the absence of clear explanations
for this finding, speculations on a possible more effective
‘graft-versus-aCML’, possibly related to minor antigens differ-
ences, rather than a possible impact of more efficacious con-
ditioning regimens in the MUD setting, are entirely open to
discussion.
Also of interest is the observed impact of the EBMT score
on survival outcome. In fact, based on age of the patient,
stage of the disease, time from diagnosis, donor type and
donor-recipient gender combination, the EBMT score (Grat-
wohl score) has been originally created to assess the risk of
death in patients with Philadelphia-positive CML undergoing
allo-HSCT (Gratwohl et al, 1998). It provides a simple tool
to predict outcome in terms of survival and NRM in patients
who are candidates for transplantation. Since then, the
EBMT score has also been effectively associated with trans-
plant outcome in other acute and chronic haematological
malignancies (Gratwohl et al, 2009). Its applicability in the
setting of aCML has been previously suggested in a small ser-
ies of patients from a single institution (Koldehoff et al,
2004). Indeed, when applied to our larger series of aCML
patients, the EBMT score appeared able to discriminate three
risk-groups with significantly different survival.
In conclusion, considering the current lack of effective
treatment options for aCML, this study confirmed that allo-
HSCT represents a valid strategy to achieve cure in a reason-
able proportion of patients, with young patients that have a
low EBMT risk score possibly being the best candidates.
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